Atypical antipsychotic drugs in dual disorders: current evidence and clinical guidelines

CONCLUSION: The findings highlight the use of SGA for the treatment of psychotic symptoms in comorbidity with substance use. Future studies on people with dual diagnosis and focused on long-term evaluations are warranted and need to investigate the efficacy of newly introduced molecules, such as partial D2 agonists and long-acting injectable antipsychotics.PMID:35747956 | DOI:10.2174/1381612828666220623092853

Source: Current Pharmaceutical Design - June 24, 2022 Category: Drugs & Pharmacology Authors: Giovanni Martinotti Stefania Chiappini Alessio Mosca Andrea Miuli Maria Chiara Santovito Mauro Pettorruso Valentin Skryabin Stefano L Sensi Massimo Di Giannantonio Source Type: research